Stocks · News reference
8-K filing — Prime Medicine, Inc. (PRME)
Filed: 2026-08-06 AccNo: 0001628280-26-053878 Size: 230 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.